202 related articles for article (PubMed ID: 32039348)
1. HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson's Disease.
Ferenci P; Pfeiffenberger J; Stättermayer AF; Stauber RE; Willheim C; Weiss KH; Munda-Steindl P; Trauner M; Schilsky M; Zoller H
JHEP Rep; 2019 May; 1(1):2-8. PubMed ID: 32039348
[TBL] [Abstract][Full Text] [Related]
2. Acute liver failure with hemolytic anemia in children with Wilson's disease: Genotype-phenotype correlations?
Pop TL; Grama A; Stefanescu AC; Willheim C; Ferenci P
World J Hepatol; 2021 Oct; 13(10):1428-1438. PubMed ID: 34786177
[TBL] [Abstract][Full Text] [Related]
3. Pediatric non-alcoholic fatty liver disease and kidney function: Effect of
Di Sessa A; Umano GR; Cirillo G; Passaro AP; Verde V; Cozzolino D; Guarino S; Marzuillo P; Miraglia Del Giudice E
World J Gastroenterol; 2020 Sep; 26(36):5474-5483. PubMed ID: 33024398
[TBL] [Abstract][Full Text] [Related]
4. Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension.
Scheiner B; Stättermayer AF; Schwabl P; Bucsics T; Paternostro R; Bauer D; Simbrunner B; Schmidt R; Marculescu R; Ferlitsch A; Peck-Radosavljevic M; Pinter M; Trauner M; Reiberger T; Ferenci P; Mandorfer M
Liver Int; 2020 Feb; 40(2):393-404. PubMed ID: 31967400
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-targeted genome editing of human induced pluripotent stem cell-derived hepatocytes for the treatment of Wilson's disease.
Wei R; Yang J; Cheng CW; Ho WI; Li N; Hu Y; Hong X; Fu J; Yang B; Liu Y; Jiang L; Lai WH; Au KW; Tsang WL; Tse YL; Ng KM; Esteban MA; Tse HF
JHEP Rep; 2022 Jan; 4(1):100389. PubMed ID: 34877514
[TBL] [Abstract][Full Text] [Related]
6. Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease.
Paternostro R; Staufer K; Traussnigg S; Stättermayer AF; Halilbasic E; Keritam O; Meyer EL; Stift J; Wrba F; Sipos B; Canbay A; Schlattjan M; Aigner E; Datz C; Stickel F; Schafmayer C; Hampe J; Buch S; Prager G; Munda P; Mandorfer M; Ferenci P; Trauner M
Hepatol Int; 2021 Aug; 15(4):922-933. PubMed ID: 34076851
[TBL] [Abstract][Full Text] [Related]
7. Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis.
Tang S; Zhang J; Mei TT; Zhang WY; Zheng SJ; Yu HB
BMC Gastroenterol; 2021 Dec; 21(1):490. PubMed ID: 34930143
[TBL] [Abstract][Full Text] [Related]
8. The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease.
Sun DQ; Wang TY; Zheng KI; Zhang HY; Wang XD; Targher G; Byrne CD; Chen YP; Yuan WJ; Jin Y; Zheng MH
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1822-1831. PubMed ID: 33853719
[TBL] [Abstract][Full Text] [Related]
9. Genetic variant rs72613567 of HSD17B13 gene reduces alcohol-related liver disease risk in Chinese Han population.
Chen H; Zhang Y; Guo T; Yang F; Mao Y; Li L; Liu C; Gao H; Jin Y; Che Y; Li Y; Huang J
Liver Int; 2020 Sep; 40(9):2194-2202. PubMed ID: 33151633
[TBL] [Abstract][Full Text] [Related]
10. High Risk of Fatty Liver Disease Amplifies the Alanine Transaminase-Lowering Effect of a HSD17B13 Variant.
Gellert-Kristensen H; Nordestgaard BG; Tybjaerg-Hansen A; Stender S
Hepatology; 2020 Jan; 71(1):56-66. PubMed ID: 31155741
[TBL] [Abstract][Full Text] [Related]
11. Late-onset Wilson's disease.
Ferenci P; Członkowska A; Merle U; Ferenc S; Gromadzka G; Yurdaydin C; Vogel W; Bruha R; Schmidt HT; Stremmel W
Gastroenterology; 2007 Apr; 132(4):1294-8. PubMed ID: 17433323
[TBL] [Abstract][Full Text] [Related]
12. A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
Abul-Husn NS; Cheng X; Li AH; Xin Y; Schurmann C; Stevis P; Liu Y; Kozlitina J; Stender S; Wood GC; Stepanchick AN; Still MD; McCarthy S; O'Dushlaine C; Packer JS; Balasubramanian S; Gosalia N; Esopi D; Kim SY; Mukherjee S; Lopez AE; Fuller ED; Penn J; Chu X; Luo JZ; Mirshahi UL; Carey DJ; Still CD; Feldman MD; Small A; Damrauer SM; Rader DJ; Zambrowicz B; Olson W; Murphy AJ; Borecki IB; Shuldiner AR; Reid JG; Overton JD; Yancopoulos GD; Hobbs HH; Cohen JC; Gottesman O; Teslovich TM; Baras A; Mirshahi T; Gromada J; Dewey FE
N Engl J Med; 2018 Mar; 378(12):1096-1106. PubMed ID: 29562163
[TBL] [Abstract][Full Text] [Related]
13. A 17-Beta-Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease.
Yang J; Trépo E; Nahon P; Cao Q; Moreno C; Letouzé E; Imbeaud S; Bayard Q; Gustot T; Deviere J; Bioulac-Sage P; Calderaro J; Ganne-Carrié N; Laurent A; Blanc JF; Guyot E; Sutton A; Ziol M; Zucman-Rossi J; Nault JC
Hepatology; 2019 Jul; 70(1):231-240. PubMed ID: 30908678
[TBL] [Abstract][Full Text] [Related]
14. Impact of a Loss-of-Function Variant in
Gil-Gómez A; Rojas Á; García-Lozano MR; Muñoz-Hernández R; Gallego-Durán R; Maya-Miles D; Montero-Vallejo R; Gato S; Gallego J; Francés R; Soriano G; Ampuero J; Romero-Gómez M
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233142
[TBL] [Abstract][Full Text] [Related]
15. HSD17B13 rs72613567 protects against liver diseases and histological progression of nonalcoholic fatty liver disease: a systematic review and meta-analysis.
Wang P; Wu CX; Li Y; Shen N
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8997-9007. PubMed ID: 32964989
[TBL] [Abstract][Full Text] [Related]
16. Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease.
Liu WY; Eslam M; Zheng KI; Ma HL; Rios RS; Lv MZ; Li G; Tang LJ; Zhu PW; Wang XD; Byrne CD; Targher G; George J; Zheng MH
J Clin Transl Hepatol; 2021 Apr; 9(2):194-202. PubMed ID: 34007801
[TBL] [Abstract][Full Text] [Related]
17. High frequency of the c.3207C>A (p.H1069Q) mutation in ATP7B gene of Lithuanian patients with hepatic presentation of Wilson's disease.
Kucinskas L; Jeroch J; Vitkauskiene A; Sakalauskas R; Petrenkiene V; Kucinskas V; Naginiene R; Schmidt H; Kupcinskas L
World J Gastroenterol; 2008 Oct; 14(38):5876-9. PubMed ID: 18855987
[TBL] [Abstract][Full Text] [Related]
18. Attenuated effect of PNPLA3 on hepatic fibrosis by HSD17B13 in Japanese patients with non-alcoholic fatty liver disease.
Seko Y; Yamaguchi K; Tochiki N; Yano K; Takahashi A; Okishio S; Kataoka S; Okuda K; Umemura A; Moriguchi M; Tanaka S; Mori K; Okanoue T; Itoh Y
Liver Int; 2020 Jul; 40(7):1686-1692. PubMed ID: 32342668
[TBL] [Abstract][Full Text] [Related]
19. Association of HSD17B13 rs72613567:TA with non-alcoholic fatty liver disease in Hispanics/Latinos.
Kallwitz E; Tayo BO; Kuniholm MH; Daviglus M; Zeng D; Isasi CR; Cotler SJ
Liver Int; 2020 Apr; 40(4):889-893. PubMed ID: 31965669
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers for diagnosis of Wilson's disease.
Ryan A; Nevitt SJ; Tuohy O; Cook P
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31743430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
